MX369019B - Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos. - Google Patents

Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos.

Info

Publication number
MX369019B
MX369019B MX2013013409A MX2013013409A MX369019B MX 369019 B MX369019 B MX 369019B MX 2013013409 A MX2013013409 A MX 2013013409A MX 2013013409 A MX2013013409 A MX 2013013409A MX 369019 B MX369019 B MX 369019B
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
compounds
pharmaceutical compositions
vii
Prior art date
Application number
MX2013013409A
Other languages
English (en)
Other versions
MX2013013409A (es
Inventor
Gennadievich Shurygin Mikhail
Aleksandrovna Shurygina Irina
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2011119848/15A external-priority patent/RU2011119848A/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of MX2013013409A publication Critical patent/MX2013013409A/es
Publication of MX369019B publication Critical patent/MX369019B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
    • C08L79/06—Polyhydrazides; Polytriazoles; Polyamino-triazoles; Polyoxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La invención se refiere al campo de la farmacéutica, la medicina clínica y experimental y la medicina veterinaria, y en particular, a nuevos compuestos inhibidores de una quinasa MAP p38 con una estructura de tipo (I) - (VII) que puede ser utilizada para el tratamiento y la prevención de adherencias. La invención describe composiciones farmacéuticas que contienen una cantidad efectiva de la sustancia SB203580 o uno de los compuestos de tipo (I) - (VII) o una combinación de los mismos y un portador, diluyente o excipiente farmacéuticamente aceptable. También, se describe el uso de la sustancia SB203580 como un agente que tiene actividad anti-adherencia. Además se describe: un método para la prevención y/o tratamiento de una enfermedad o condición en el que existe la posibilidad de formación y/o crecimiento de adherencias lo que hace posible prescindir de la administración adicional de una preparación en el período postoperatorio.
MX2013013409A 2011-05-17 2012-05-17 Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos. MX369019B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (ru) 2011-05-17 2011-05-17 Способ профилактики спайкообразования
RU2011153043 2011-12-26
PCT/IB2012/052483 WO2012156938A1 (ru) 2011-05-17 2012-05-17 Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса

Publications (2)

Publication Number Publication Date
MX2013013409A MX2013013409A (es) 2014-07-11
MX369019B true MX369019B (es) 2019-10-24

Family

ID=47176372

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013013409A MX369019B (es) 2011-05-17 2012-05-17 Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos.
MX2019011386A MX2019011386A (es) 2011-05-17 2013-11-15 Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019011386A MX2019011386A (es) 2011-05-17 2013-11-15 Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.

Country Status (31)

Country Link
US (2) US10172952B2 (es)
EP (2) EP3569636A1 (es)
JP (2) JP5936683B2 (es)
KR (2) KR20140074259A (es)
CN (1) CN103534293B (es)
AP (1) AP3694A (es)
AU (3) AU2012257347A1 (es)
BR (1) BR112013029616B1 (es)
CA (1) CA2836268C (es)
CL (1) CL2013003305A1 (es)
CO (1) CO6801779A2 (es)
CR (1) CR20130600A (es)
CY (1) CY1122190T1 (es)
DK (1) DK2716684T3 (es)
DO (1) DOP2013000266A (es)
EA (1) EA025493B1 (es)
GE (1) GEP201706614B (es)
HK (1) HK1189012A1 (es)
IL (1) IL229423B (es)
LT (1) LT2716684T (es)
MA (1) MA35189B1 (es)
MX (2) MX369019B (es)
NI (1) NI201300124A (es)
PE (1) PE20141161A1 (es)
PL (1) PL2716684T3 (es)
RS (1) RS59382B1 (es)
RU (1) RU2582975C2 (es)
SI (1) SI2716684T1 (es)
SV (1) SV2013004582A (es)
WO (1) WO2012156938A1 (es)
ZA (1) ZA201308542B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5936683B2 (ja) * 2011-05-17 2016-06-22 ジョイント ストック カンパニー ”ファーマシンテズ” 癒着の治療及び予防のための化合物、医薬組成物及び方法
RU2745965C1 (ru) * 2020-11-23 2021-04-05 Галина Анатольевна Пучкина Способ профилактики послеоперационного спаечного процесса органов малого таза
RU2749435C1 (ru) * 2020-11-27 2021-06-10 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Способ лечения энтеральной недостаточности при воспалительных и травматических повреждениях брюшины

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
EP0871444A4 (en) * 1995-08-10 1999-01-13 Merck & Co Inc 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5894971A (en) 1998-02-02 1999-04-20 Huang; Te Chien Tool holder for attaching tools to user's hand
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
EA005532B1 (ru) * 2000-08-17 2005-04-28 Пфайзер Инк. Замещенные имидазолы в качестве ингибиторов активированной формы активируемого тромбином ингибитора фибринолиза (tafia)
WO2004005264A2 (en) * 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
AU2003303513A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
JP2009508938A (ja) * 2005-09-22 2009-03-05 ハダシット メディカル リサーチ サーヴィスィズ アンド ディベロップメント リミテッド 治療上活性な化合物の結合体
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
EP2195039B1 (en) * 2007-08-28 2016-11-30 Otago Innovation Limited Surgical hydrogel
RU2363476C1 (ru) 2007-12-20 2009-08-10 Марина Сергеевна Гомон Способ профилактики образования послеоперационных спаек
WO2009103821A2 (de) * 2008-02-23 2009-08-27 Virologik Gmbh Mittel zur behandlung von virusinfektionen
US8205286B1 (en) 2008-10-21 2012-06-26 Milagros Diaz Pillow for female breasts
JP5936683B2 (ja) * 2011-05-17 2016-06-22 ジョイント ストック カンパニー ”ファーマシンテズ” 癒着の治療及び予防のための化合物、医薬組成物及び方法
CA2846143A1 (en) 2013-03-13 2014-09-13 Evan J. Falck Helmet pillow

Also Published As

Publication number Publication date
KR20140074259A (ko) 2014-06-17
PE20141161A1 (es) 2014-10-01
ZA201308542B (en) 2014-07-30
GEP201706614B (en) 2017-02-10
AP3694A (en) 2016-04-30
MX2013013409A (es) 2014-07-11
CN103534293B (zh) 2015-10-21
US20190125886A1 (en) 2019-05-02
RU2582975C2 (ru) 2016-04-27
AU2017221883A1 (en) 2017-09-28
EP2716684A4 (en) 2015-07-15
EP2716684A1 (en) 2014-04-09
JP2014515057A (ja) 2014-06-26
NI201300124A (es) 2014-02-25
SV2013004582A (es) 2018-11-12
NZ618882A (en) 2016-03-31
CY1122190T1 (el) 2020-11-25
CO6801779A2 (es) 2013-11-29
BR112013029616A2 (pt) 2020-08-25
CA2836268A1 (en) 2012-11-22
RS59382B1 (sr) 2019-11-29
EA201301275A1 (ru) 2014-03-31
EP2716684B1 (en) 2019-06-26
CR20130600A (es) 2014-04-29
JP5936683B2 (ja) 2016-06-22
HK1189012A1 (en) 2014-05-23
RU2013155582A (ru) 2015-06-27
SI2716684T1 (sl) 2019-11-29
AU2012257347A1 (en) 2014-01-09
MX2019011386A (es) 2019-10-30
IL229423A0 (en) 2014-01-30
MA35189B1 (fr) 2014-06-02
AU2015213303A1 (en) 2015-09-03
PL2716684T3 (pl) 2020-01-31
CA2836268C (en) 2018-07-03
LT2716684T (lt) 2019-09-25
EP3569636A1 (en) 2019-11-20
IL229423B (en) 2018-04-30
WO2012156938A1 (ru) 2012-11-22
JP2016175931A (ja) 2016-10-06
US20140079663A1 (en) 2014-03-20
CN103534293A (zh) 2014-01-22
BR112013029616B1 (pt) 2022-09-20
AP2013007258A0 (en) 2013-11-30
KR20170034950A (ko) 2017-03-29
CL2013003305A1 (es) 2014-07-18
EA025493B1 (ru) 2016-12-30
DOP2013000266A (es) 2014-06-01
US10493164B2 (en) 2019-12-03
US10172952B2 (en) 2019-01-08
AU2017221883B2 (en) 2019-06-20
DK2716684T3 (da) 2019-09-30

Similar Documents

Publication Publication Date Title
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NI201100194A (es) Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
NZ588830A (en) Inhibitors of protein kinases
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013010795A (es) 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2).
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MX2009004908A (es) Compuestos quimicos.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.

Legal Events

Date Code Title Description
FG Grant or registration